- Preliminary results for the full year of 2020: Sales revenue up 34.6 percent; underlying EBITDA margin climbs to 31.7 percent
- Sartorius Stedim Biotech plays a key role as a provider of essential technologies for vaccine production
- Number of employees rises by 21.6 percent to more than 7,500
- Strong outlook for 2021: Sales revenue set to grow by 20 percent to 26 percent
- Group management raises sales target for 2025 to 4 billion euros
PR Newswire
AUBAGNE, France, Jan. 27, 2021